4 & 5 February, 2026  |  Free Online Conference
Welcome to the Antimicrobial Chemotherapy Conference 2026.
This open-access, virtual conference was jointly organised by GARDP and BSAC. For ACC2026, the collaborating organisations were ADVANCE-ID and Mahidol University. This conference is RCPath CPD approved (8 credits).

ACC2026 Programme

Programme details below.

Download the ACC2026 brochure here
Download

Access the ACC2026 posters here
View posters

Click here to explore our past conferences: ACC2025, ACC2024, ACC2023, ACC2022. Recordings and programmes of our earlier conferences (2019, 2021) can be found here.

Select to see different time zones. Default is GMT. Time Zone Converter – Time Difference Calculator


Session one: Keynote presentation

View session one. This video consists of the following presentations:

Watch Presentation

Introductory remarks

Dr Mike Allen, Regional Medical Advisor (Antibiotics), MSD UK - View Bio

Optimising multinational clinical trials with antimicrobials, the key role of clinical trial networks

Professor David Paterson, National University of Singapore & ADVANCE-ID - View Bio

Session two: Drug discovery: new targets and new chemistry

View session two. This video consists of the following presentations:

Watch Presentation

Old drugs, new connections: a systems view on antimicrobial resistance

Dr Elisabetta Cacace, ETH Zurich - View Bio

Discovery of lariocidin: A knotty solution to antimicrobial resistance

Dr Manoj Jangra, McMaster University - View Bio

Cyclic-di-GMP signaling as a target for biofilm control

Professor Tim Tolker-Nielsen, University of Copenhagen - View Bio

Q&A

Session three: Preclinical antimicrobial development

View session three. This video consists of the following presentations:

Watch Presentation

Lysin Biotherapeutics: From Microbiome Modification to the Clearance of Severe Invasive Infections

Dr Assaf Raz, Precisio Biotix Therapeutics - View Bio

Extracellular strategies: Anti-virulence therapies to halt chronic multidrug resistant infections

Dr Christopher Jonkergouw, Arivin Therapeutics - View Bio

Q&A

Session four: Panel discussion - Equitable TB care: Closing the treatment gap for vulnerable populations

View session four. This video consists of the following presentations:

Watch Presentation

Panellists:

Professor Nick Paton, National University of Singapore & The London School of Hygiene and Tropical Medicine - View Bio

Professor Chen-Yuan Chiang, Wan Fang Hospital, Taipei Medical University, Taiwan - View Bio

Dr Wanatpreeya Phongsamart, Siriraj Hospital, Mahidol University, Bangkok, Thailand - View Bio

Q&A

Closing remarks

Dr François Franceschi, GARDP - View Bio

Session five: Clinical development and use of new agents

View session five. This video consists of the following presentations:

Watch Presentation

Introductory remarks

Dr François Franceschi, GARDP - View Bio

Novel antibiotic combination for A. baumannii

Dr Glenn Dale, BioVersys - View Bio

Chlamydia trachomatis vaccine development

Dr Alvaro Borges, Statens Serum Institut - View Bio

The clinical development of gepotidacin: a novel oral antibiotic for the treatment of uncomplicated UTI

Dr Jeremy Dennison, GSK - View Bio

Q&A

Session six: Oral poster presentations

View session six. This video consists of the following presentations:

Watch Presentation

Investigating the aetiology and contribution of antimicrobial-resistant infections to illness and death among hospitalised adults with advanced HIV disease: observations from a retrospective cohort in South Africa

Dr Emily Prendergast, University of the Witwatersrand, Johannesburg

Co-Resistance mapping of Ciprofloxacin and Ceftriaxone in Uropathogenic E. coli and Klebsiella

Hena Sojitra, Krishna School of Science, India

Post-fluoroquinolone treatment molecular events and nutrient availability modulate Staphylococcus aureus antibiotic persistence

Dr Nisha Mahey, UConn Health, USA

Reviving the activity of antibacterial agents against Gram negative bacteria

Elissar Mansour, University of Sydney, Australia

Widespread Colonization by the Candida parapsilosis species complex in Spanish Critical Care Units

Laura Alguacil Cuéllar, Instituto de Salud Carlos III, Spain

Q&A

Session seven: From womb to world: Antimicrobial innovation for pregnancy and childhood

View session seven. This video consists of the following presentations:

Watch Presentation

Crossing the placenta: The case for including pregnant women in antimicrobial trials

Dr Sumati Nambiar, Johnson and Johnson - View Bio

STIs and silent harm: Maternal infections and neonatal sepsis

Dr Teodora Elvira C. Wi, World Health Organization - View Bio

Tiny doses, big stakes: Designing antibiotics for neonates and children

Professor Julia Bielicki, University Children’s Hospital Basel & City St George’s, University of London - View Bio

Q&A

Session eight: Panel discussion - Access isn’t the end, it’s the beginning: Reclaiming the purpose of antibiotic innovation

View session eight. This video consists of the following presentations:

Watch Presentation

Panellists:

Dr Manica Balasegaram, GARDP - View Bio

Dr Anita Kotwani, University of Delhi - View Bio

Dr Jeffrey Smith, Unitaid - View Bio

Q&A

Closing remarks

Dr Mike Allen, Regional Medical Advisor (Antibiotics), MSD UK - View Bio